Raymond James & Associates Has $1.04 Million Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Raymond James & Associates boosted its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 3.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 101,006 shares of the company’s stock after buying an additional 3,018 shares during the quarter. Raymond James & Associates’ holdings in Nurix Therapeutics were worth $1,042,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of NRIX. BlackRock Inc. boosted its stake in shares of Nurix Therapeutics by 5.3% during the 2nd quarter. BlackRock Inc. now owns 4,519,377 shares of the company’s stock worth $45,149,000 after acquiring an additional 228,237 shares in the last quarter. Wasatch Advisors LP lifted its holdings in Nurix Therapeutics by 25.0% in the 1st quarter. Wasatch Advisors LP now owns 3,174,002 shares of the company’s stock worth $28,185,000 after purchasing an additional 635,370 shares during the last quarter. Vanguard Group Inc. boosted its position in Nurix Therapeutics by 0.8% during the third quarter. Vanguard Group Inc. now owns 2,714,845 shares of the company’s stock worth $21,339,000 after purchasing an additional 22,804 shares during the period. ARK Investment Management LLC grew its holdings in Nurix Therapeutics by 14.7% during the third quarter. ARK Investment Management LLC now owns 2,593,047 shares of the company’s stock valued at $20,381,000 after purchasing an additional 331,976 shares during the last quarter. Finally, State Street Corp raised its position in shares of Nurix Therapeutics by 9.2% in the third quarter. State Street Corp now owns 2,312,224 shares of the company’s stock valued at $30,128,000 after purchasing an additional 195,453 shares during the period.

Insider Activity

In related news, CFO Houte Hans Van sold 6,812 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $10.02, for a total value of $68,256.24. Following the completion of the transaction, the chief financial officer now directly owns 68,333 shares of the company’s stock, valued at $684,696.66. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last ninety days, insiders have sold 10,817 shares of company stock worth $100,256. Company insiders own 7.20% of the company’s stock.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $13.59 on Monday. The firm’s 50-day moving average is $13.23 and its 200-day moving average is $9.52. The company has a market cap of $667.96 million, a price-to-earnings ratio of -5.11 and a beta of 2.06. Nurix Therapeutics, Inc. has a 52-week low of $4.22 and a 52-week high of $18.12.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The firm had revenue of $15.16 million for the quarter, compared to the consensus estimate of $30.66 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. Equities analysts predict that Nurix Therapeutics, Inc. will post -3.15 EPS for the current year.

Wall Street Analyst Weigh In

NRIX has been the subject of several recent analyst reports. Wells Fargo & Company decreased their price objective on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Friday, February 16th. Royal Bank of Canada upped their price target on shares of Nurix Therapeutics from $22.00 to $23.00 and gave the company an “outperform” rating in a report on Thursday, April 11th. Needham & Company LLC reiterated a “buy” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, April 9th. Robert W. Baird increased their target price on Nurix Therapeutics from $24.00 to $25.00 and gave the company an “outperform” rating in a research note on Thursday, April 11th. Finally, Morgan Stanley raised their target price on Nurix Therapeutics from $9.00 to $10.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.33.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.